Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 1
2010 2
2011 3
2012 1
2013 2
2014 3
2015 1
2017 1
2018 3
2019 3
2020 5
2021 2
2022 4
2023 8
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis.
Wijnands AM, de Jong ME, Lutgens MWMD, Hoentjen F, Elias SG, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Wijnands AM, et al. Gastroenterology. 2021 Apr;160(5):1584-1598. doi: 10.1053/j.gastro.2020.12.036. Epub 2020 Dec 29. Gastroenterology. 2021. PMID: 33385426 Free article.
BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC). We performed a systematic review and meta-analysis to identify all prognostic factors for advanced colorectal neoplasia (aCRN, high-grade dysplasia, or CR …
BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC). We performed a …
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Biemans VBC, et al. Aliment Pharmacol Ther. 2020 May;51(9):880-888. doi: 10.1111/apt.15689. Epub 2020 Apr 1. Aliment Pharmacol Ther. 2020. PMID: 32237087 Free PMC article.
Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.
Wijnands AM, Penning de Vries BBL, Lutgens MWMD, Bakhshi Z, Al Bakir I, Beaugerie L, Bernstein CN, Chang-Ho Choi R, Coelho-Prabhu N, Graham TA, Hart AL, Ten Hove JR, Itzkowitz SH, Kirchgesner J, Mooiweer E, Shaffer SR, Shah SC, Elias SG, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Wijnands AM, et al. Clin Gastroenterol Hepatol. 2024 Aug;22(8):1697-1708. doi: 10.1016/j.cgh.2024.02.014. Epub 2024 Feb 29. Clin Gastroenterol Hepatol. 2024. PMID: 38431223 Free article.
BACKGROUND & AIMS: Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their increased risk of colorectal cancer (CRC). We aimed to develop and validate a dynamic prediction model for the occurrence of advanced color …
BACKGROUND & AIMS: Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their …
Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis.
Simsek M, Lissenberg-Witte BI, van Riswijk MLM, Verschuren S, Hoentjen F, Oldenburg B, Ponsioen CY, van der Woude CJ, van der Meulen AE, Pierik M, Dijkstra G, de Boer NKH; Parelsnoer Institute (PSI), the Dutch Initiative on Crohn's and Colitis (ICC). Simsek M, et al. Aliment Pharmacol Ther. 2019 May;49(10):1293-1300. doi: 10.1111/apt.15229. Epub 2019 Mar 25. Aliment Pharmacol Ther. 2019. PMID: 30908719 Free PMC article.
Drugs were classified as off-label if they were unlicensed for Crohn's disease and/or ulcerative colitis by the Medicines Evaluation Board. Uni- and multivariable analyses were used to identify patient-specific characteristics predictive of increased off-labe …
Drugs were classified as off-label if they were unlicensed for Crohn's disease and/or ulcerative colitis by the Medicin …
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NSM, Mares WGN, Mahmmod N, van Asseldonk DP, Lutgens MWMD, Kuyvenhoven JP, Rietdijk ST, Nissen LHC, Koehestanie P, de Boer NKH, de Jonge R, Bouma G, Bulatović Ćalasan M; Dutch Initiative on Crohn and Colitis (ICC). van de Meeberg MM, et al. Aliment Pharmacol Ther. 2023 Dec;58(11-12):1151-1162. doi: 10.1111/apt.17719. Epub 2023 Sep 28. Aliment Pharmacol Ther. 2023. PMID: 37767910
Measuring methotrexate-polyglutamate (MTX-PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease (CD). AIM: To investigate the relationship between MTX-PGs and methotrexate drug survival, efficacy and toxicity METHODS: In a mul …
Measuring methotrexate-polyglutamate (MTX-PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's di …
Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn's Disease.
Bak MTJ, Ten Bokkel Huinink S, Erler NS, Bodelier AGL, Dijkstra G, Romberg-Camps M, de Boer NKH, Hoentjen F, Stassen LPS, van der Meulen-de Jong AE, West RL, van Ruler O, van der Woude CJ, de Vries AC; Dutch Initiative on Crohn and Colitis (ICC). Bak MTJ, et al. Am J Gastroenterol. 2024 Feb 1;119(2):306-312. doi: 10.14309/ajg.0000000000002509. Epub 2023 Nov 1. Am J Gastroenterol. 2024. PMID: 37737675 Free PMC article.
INTRODUCTION: The prognostic value of the modified Rutgeerts score (mRS) in patients with Crohn's disease (CD) needs to be further elucidated. This study assessed the prognostic value of the mRS for long-term outcomes after primary ileocecal resection in pati …
INTRODUCTION: The prognostic value of the modified Rutgeerts score (mRS) in patients with Crohn's disease (CD) needs to …
Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose-effect relationship.
Wijnands AM, Elias SG, Dekker E, Fidder HH, Hoentjen F, Ten Hove JR, Maljaars PWJ, van der Meulen-de Jong AE, Mooiweer E, Ouwehand RJ, Penning de Vries BBL, Ponsioen CY, van Schaik FDM, Oldenburg B; Dutch Initiative on Crohn's and Colitis (ICC). Wijnands AM, et al. United European Gastroenterol J. 2023 Sep;11(7):612-620. doi: 10.1002/ueg2.12426. Epub 2023 Jul 28. United European Gastroenterol J. 2023. PMID: 37505117 Free PMC article.
We aimed to further elucidate the association between smoking, including possible dose-effects, and the development of colorectal neoplasia in patients with inflammatory bowel disease (IBD). METHODS: We performed a prospective multicenter cohort study including patients wi …
We aimed to further elucidate the association between smoking, including possible dose-effects, and the development of colorectal neoplasia …
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R, Savelkoul EHJ, Mares W, Goetgebuer R, Witteman BJM, de Koning DB, van Tuyl SAC, Minderhoud I, Lutgens MWMD, Akol-Simsek D, van Schaik FDM, Fidder HH, Jansen JM, van Boeckel PGA, Mahmmod N, Horjus-Talabur Horje CS, Römkens TEH, Colombel JF, Hoentjen F, Jharap B, Oldenburg B; Dutch Initiative on Crohn’s and Colitis (ICC) and the AWARE study group. Mahmoud R, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):750-760.e4. doi: 10.1016/j.cgh.2022.08.024. Epub 2022 Aug 31. Clin Gastroenterol Hepatol. 2023. PMID: 36055567 Free article.
BACKGROUND & AIMS: Discontinuation of anti-tumor necrosis factor-alpha treatment (anti-TNF) (infliximab and adalimumab) in patients with inflammatory bowel disease (IBD) is associated with a high relapse risk that may be influenced by endoscopic activity at the time of …
BACKGROUND & AIMS: Discontinuation of anti-tumor necrosis factor-alpha treatment (anti-TNF) (infliximab and adalimumab) in patients with …
Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G; Dutch Initiative on Crohn and Colitis (ICC). Hommes DW, et al. Neth J Med. 2006 Jul-Aug;64(7):219-29. Neth J Med. 2006. PMID: 16929083 Free article. Review.
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The effectiveness of infliximab has been demonstrated for both active luminal disease and for enterocutaneous fistulisation. In addition, infliximab can be …
Infliximab is an accepted induction and maintenance treatment for patients with Crohn's disease. The effectiveness of i …
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group, the Dutch Initiative on Crohn, Colitis (ICC). van Linschoten RCA, et al. Dig Dis Sci. 2024 Jun;69(6):2165-2174. doi: 10.1007/s10620-024-08410-z. Epub 2024 Apr 9. Dig Dis Sci. 2024. PMID: 38594435 Free PMC article. Clinical Trial.
BACKGROUND: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn's disease (CD) in clinical …
BACKGROUND: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose int …
35 results